ReviewFrontiers in medicine2023
Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review.
Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Apalutamide-induced drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson syndrome overlap successfully treated with cyclosporine and benralizumab: A case report and literature review.JAAD case reports · 2026Article
- Delayed Drug Hypersensitivity: Mechanistic Advances and Emerging Therapies.Current allergy and asthma reports · 2026Review
- Possible CPX-351-associated drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome-like reaction during severe lymphopenia.Annals of hematology · 2026Article
- Allopurinol-associated Drug Reaction with Eosinophilia and Systemic Symptom Syndrome: A Severe Delayed Drug Hypersensitivity Reaction.Annals of African medicine · 2026Article
- Enalapril, Atenolol, Alendronate and DRESS Syndrome - A Case Report.Acta dermato-venereologica · 2026Article
- New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report.Clinical and translational allergy · 2026Review
- Distinct cytokine and chemokine alterations in bronchoalveolar fluid from patients with systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD).Arthritis research & therapy · 2026Article
- Utility of Patch Testing, LTT, and HLA Genotyping in Identifying Culprit Drugs and Diagnosing Multiple Drug Hypersensitivity in Definite DRESS: A 10-Year Cohort Study.Clinical and translational allergy · 2026Article
- Immunological and Inflammatory Characteristics of Severe Cutaneous Adverse Drug Reactions: A Retrospective Study.International journal of general medicine · 2026Article
- TNF-α blockade for carbamazepine-induced drug reaction with eosinophilia and systemic symptoms.Frontiers in immunology · 2026Article
- Th2-High Severe Asthma with Hypereosinophilia in the Spectrum of Type 2 Inflammatory Diseases.International journal of molecular sciences · 2025Review
- DRESS syndrome secondary to phenytoin: a case report and review of the literature.Annals of medicine and surgery (2012) · 2025Article
- Severe cutaneous adverse reactions to anti-osteoporosis drugs: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database and a review of published cases.Frontiers in pharmacology · 2025Article
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Retrospective Study of 51 Chinese Patients.Clinical, cosmetic and investigational dermatology · 2025Article
- DRESS Mimicking Flushing Syndrome Associated with Vancomycin: A Case Report.Current drug safety · 2025Article
- Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications.Frontiers in pharmacology · 2025Review
- Severe Hypersensitivity Reactions with Oral Manifestations: Case Reports on Stevens-Johnson Syndrome and DRESS Syndrome.Journal of pharmacy & bioallied sciences · 2024Article
- Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses.The journal of allergy and clinical immunology. In practice · 2024Article
- Bilateral purtscher-like retinopathy associated with DRESS syndrome: a case report.Journal of ophthalmic inflammation and infection · 2024Article
- Drug-induced hypersensitivity syndrome related to piperacillin-tazobactam: a case report and review of the literature.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug reaction with eosinophilia and systemic symptoms or drug-induced hypersensitivity syndrome (DRESS/DIHS) is one type of severe cutaneous adverse reaction (SCAR). It is featured by fever, widespread skin lesions, protracted clinical course, internal organ involvement, and possibly long-term autoimmune sequelae. The presence of high-risk human leukocyte antigen (HLA) alleles, hypersensitivity reaction after culprit drug ingestion, and human herpesvirus reactivation may all contribute to its complex clinical manifestations. Some recent studies focusing on the roles of involved cytokines/chemokines and T cells co-signaling pathways in DRESS/DIHS were conducted. In addition, some predictors of disease severity and prognosis were also reported. In this review, we provided an update on the current understanding of the pathogenesis, potential biomarkers, and the relevant therapeutic rationales of DRESS/DIHS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.